Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers

Abstract Background: Lersivirine is a nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of HIV-1. Objective: The goal of this study was to investigate the safety and tolerability of multiple oral doses of lersivirine administered to healthy male subjects...

Ausführliche Beschreibung